Alvotech and Teva Secure U.S. Settlement for Eylea Biosimilar AVT06 Launch in Q4 2026
核心洞察
Alvotech and Teva reached a settlement agreement with Regeneron allowing U.S. market entry for AVT06, a proposed biosimilar to Eylea (aflibercept), in the fourth quarter of 2026.
AVT06 has already received marketing approvals in Europe, Japan, and the UK, with clinical studies demonstrating high similarity to the reference product in treating neovascular AMD.
The settlement positions both companies for a potential U.S. launch pending FDA approval, following positive confirmatory clinical trial results announced in January 2024.
Alvotech and Teva Pharmaceuticals have secured a critical settlement agreement with Regeneron Pharmaceuticals that clears the path for U.S. market entry of AVT06, a proposed biosimilar to the blockbuster retinal disease treatment Eylea (aflibercept). The settlement grants a license entry date for AVT06 in the United States in the fourth quarter of 2026, or earlier under certain circumstances.
The agreement represents a significant milestone for both companies, building on recent international approvals for the biosimilar candidate. "Following recent marketing approvals in both Europe and Japan, we are delighted to secure a U.S. settlement date for our biosimilar candidate to Eylea, an important biologic for the treatment of retinal diseases (搜索)," said Robert Wessman, Chairman and CEO of Alvotech.
International Market Success
AVT06 has already demonstrated regulatory success across multiple markets, receiving approval for marketing as an aflibercept biosimilar in the United Kingdom, Japan, and the 30 countries of the European Economic Area. The biosimilar is marketed under the brand name Mynzepli (aflibercept) in the UK and European Economic Area, and as AFLIBERCEPT BS in Japan.
The European Economic Area approval encompasses all 27 member states of the European Union in addition to Norway, Iceland, and Liechtenstein, providing Alvotech with access to a substantial patient population across these regions.
Clinical Evidence Supporting Biosimilarity
The settlement follows positive clinical data supporting AVT06's biosimilarity to the reference product. In January 2024, Alvotech announced positive top-line results from a confirmatory clinical study comparing the efficacy, safety, and immunogenicity of AVT06 to Eylea in patients with neovascular (wet) age-related macular degeneration (AMD).
The randomized, double-masked parallel-group, multicenter clinical study met its primary endpoint, with results demonstrating high similarity between Alvotech's biosimilar candidate and Eylea. The study design and outcomes provide the regulatory foundation supporting the biosimilar's approval across multiple jurisdictions.
Mechanism of Action and Therapeutic Application
AVT06 functions through the same mechanism as its reference product, binding vascular endothelial growth factors (搜索) (VEGF (搜索)) and inhibiting the binding and activation of VEGF receptors (搜索), neovascularization, and vascular permeability. This mechanism makes it an important therapeutic option for treating retinal diseases (搜索), particularly neovascular AMD.
The settlement positions Alvotech and Teva for what Wessman described as "a successful launch in the U.S. market next year, pending FDA approval." The timing aligns with the companies' strategic planning for market entry in one of the world's largest pharmaceutical markets.
Strategic Partnership and Market Positioning
The collaboration between Alvotech and Teva leverages both companies' strengths in biosimilar development and commercialization. Alvotech, founded by Robert Wessman, focuses solely on the development and manufacture of biosimilar medicines, while Teva brings extensive commercial expertise and market access capabilities.
Alvotech's current pipeline includes eight disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disease, osteoporosis, respiratory disease, and cancer. The company has established a network of strategic commercial partnerships to provide global reach across the United States, Europe, Japan, China, other Asian countries, and large parts of South America, Africa, and the Middle East.
The settlement agreement represents a crucial step in bringing increased treatment options and potential cost savings to patients with retinal diseases (搜索) in the United States, pending final FDA approval of AVT06.